Trial · NCT07878052
Resting Metabolic Rate in Bodybuilders Using Performance-Enhancing Drugs
NCT07878052, Active not recruiting, Atlantica - Instituto Universitario
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Resting Metabolic Rate in Bodybuilders Using Performance-Enhancing Drugs. Trials, record NCT07878052. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07878052
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Resting Metabolic Rate in Bodybuilders Using Performance-Enhancing Drugs
- NCT number
- NCT07878052
- Status
- Active not recruiting
- Enrollment
- 62 participants, estimated
- Lead sponsor
- Atlantica - Instituto Universitario
- Conditions
- Athlete Assessment, Body Composition
- Interventions
- No Intervention: Observational Cohort
- First posted
- 2026-10-16
- Last updated
- 2026-10-16
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Resting Metabolic Rate | Baseline | Measured via indirect calorimetry using an open-circuit ventilated canopy system (Quark, Cosmed, Italy). Assessment is performed in a quiet, thermoneutral room after supine rest, following an overnight fast of 8-10 hours and at least 24 hours of abstention from exercise, caffeine, and alcohol. The average RMR will be calculated from the 5-minute steady-state period showing the lowest coefficient of variation. |
| Secondary | Fat-Free Mass (FFM) | Baseline | Assessment of whole-body fat-free mass (kg) using a whole-body DXA scanner (Hologic, USA) following standardized positioning protocols. |
| Secondary | Fat Mass (FM) | Baseline | Assessment of whole-body fat mass (kg) using a whole-body DXA scanner (Hologic, USA) following standardized positioning protocols. |
| Secondary | Total Body Water | Baseline | Assessment of total body water (liters), intracellular water (liters), and extracellular water (liters) using a phase-sensitive bioimpedance device (BIA-101, RJL/Akern Systems). |
| Secondary | Sum of 7 Skinfolds | Baseline | Measurement of subcutaneous fat thickness (sum of 7 skinfolds in millimeters using a Harpenden caliper) assessed by a certified anthropometrist according to International Society for the Advancement of Kinanthropometry (ISAK) guidelines. |
| Secondary | Body Circumferences | Baseline | Measurement and body circumferences (waist, hip, arm, thigh, calf in centimeters) assessed by a certified anthropometrist according to International Society for the Advancement of Kinanthropometry (ISAK) guidelines. |
| Other | Anabolic and Fat Burning Pharmacological Agents usage | Baseline | Characterization of pharmacological substance exposure assessed via a structured confidential questionnaire. Parameters evaluated include classes and types of compounds used in the preceding 6 months (e.g., anabolic-androgenic steroids, clenbuterol, growth hormone, thyroid hormones), cumulative duration of use (months/years), administration routes, self-reported dosages, and current phase/cycle status (blast, cruise/TRT, cutting, or off) to analyze their association with resting metabolic rate. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07878052
GET https://conductscience.org/api/trials/v1/NCT07878052/registered